Merck confirms FDA approves Keytruda combos with Padcev
Merck announced the U.S....
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
5 results loaded, newest first. End of these results.
MRK: FDA Approves KEYTRUDA
MRK's KEYTRUDA and KEYTRUDA QLEX are approved by the FDA for first-line treatment of PD-L1+ advanced triple-negative breast cancer
MRK: Approves KEYTRUDA
European Commission approves KEYTRUDA plus Padcev for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer
MRK: EU Approves Keytruda
The European Union approves Merck's Keytruda in combination with Padcev for adults with resectable muscle-invasive bladder cancer
MRK Gets EU Approval
MRK's KEYTRUDA and Padcev approved by European Commission for treatment of muscle-invasive bladder cancer